Table 1.
Clinical pathological information for metastatic melanoma patients receiving CII 1 analyzed for cfmiRs 2 in plasma samples.
| Melanoma Patients (n = 47) | |
|---|---|
| Variables | n (%) |
| Age at diagnosis, mean (SD 4) | 62.0 (13.9) |
| Age at treatment, mean (SD 4) | 65.9 (13.5) |
| <60 | 14 (29.8) |
| ≥60 | 33 (70.2) |
| Gender | |
| Male | 30 (63.8) |
| Female | 17 (36.2) |
| Treatment regimen | |
| Anti-PD-1 | 31 (65.95) |
| Anti-PD-1/anti-CTLA-4 | 16 (34.05) |
| AJCC 8th ed. Stages 3 | |
| III b/c | 24 (51.1) |
| IV a/b/c/d | 23 (48.9) |
| BRAF mutation | |
| Positive | 25 (53.2) |
| Negative | 22 (46.8) |
| CII-response based on RECIST 5 1.1 | |
| Responders | 22 (46.8) |
| Non-responders | 25 (53.2) |
| Number of metastasis | |
| 1 | 24 (51.06) |
| ≥2 | 16 (34.04) |
| unknown | 7 (14.90) |
| LDH 6 level at baseline | |
| ≤1X 7 ULN | 35 (74.5) |
| >1X ULN | 12 (23.5) |
1 CII = checkpoint immune inhibitor. 2 Cell-free microRNAs = cfmiRs. 3 AJCC 8th stage = American Joint Committee on Cancer 8th edition determined at the start date of CII. 4 SD = standard deviation. 5 RECIST = Respond Evaluation Criteria In Solid Tumors. 6 LDH = lactate dehydrogenase. 7 ULN = upper limit normal.